| |
Digital health solutions have great potential to improve the lives of people with chronic conditions. However, the use of these solutions in the commercial setting for pharma is still growing. Hear from experts at Takeda, Pfizer, and Novartis on what success looks like, how a shift in mindset can reset the path to successful development and market adoption, and much more. Download today. 
|
|
| By Annalee Armstrong Fierce Biotech recounts the top 10 clinical trial failures of 2023 that sent ripples across the industry. |
|
|
|
By James Waldron Months after hailing macrocyclic peptides as the “next wave of drug discovery,” Merck & Co. has pushed further into the space by penning a $220 million biobucks deal with Unnatural Products. |
By Angus Liu As many have feared, the FDA's investigation into secondary T-cell malignancies following treatment with existing CAR-T therapies is poised to lead to a classwide black box warning. |
By Gabrielle Masson Eli Lilly says an investigational gene therapy has restored hearing in one child who has experienced hearing loss since birth. |
By Kevin Dunleavy A federal jury has found a former Pfizer statistician guilty of insider trading after a two-week trial in Manhattan. The jury convicted Amit Dagar, 44, of Hillsborough, N.J., of using advance information on successful trial results for Pfizer’s COVID-19 treatment Paxlovid to make more than $270,000 in stock trades. |
By Zoey Becker The antibody-drug conjugate did not significantly improve survival outcomes compared with a chemotherapy alone in previously treated patients with metastatic non-small cell lung cancer. The trial outcome marks a setback in Gilead's ambition to grow its presence in the oncology sector. |
By Nick Paul Taylor Novo Nordisk has piled yet another obesity program on its plate. Seeking to build on its early lead in the blockbuster market, the Danish drugmaker has agreed to pay EraCal Therapeutics up to 235 million euros ($255 million) to work on a novel mechanism of action for controlling appetite and body weight. |
By Helen Floersh Scientists from the University of Zurich have released a new study that could explain the mechanism behind the condition—a step towards developing new treatments. |
By Nick Paul Taylor Novartis’ marketing team has received a dressing-down from the FDA. After reviewing an ad for breast cancer drug Kisqali, the agency accused Novartis of making false or misleading representations about the treatment’s efficacy. |
By Zoey Becker After several inspections and regulatory setbacks, Alvotech still has a manufacturing issue to work through. This time, the FDA flagged just one observation that the Icelandic manufacturer says is "readily addressable." |
By Conor Hale Worldwide operational sales across J&J’s medical device divisions grew 12.4% in 2023, to top $30.4 billion in total revenue, with Abiomed alone contributing 4.7%, the company said. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," Sofia Guerra and Steve Kraus from Bessemer Venture Partners sat down with Fierce Healthcare's Heather Landi to discuss the health tech sector's performance, unraveling the factors that contributed to its current state. They share what it will take to get health tech out of its current market lull and explore whether we’ll see a rebound in IPOs this year. |
|
|---|
|
|
Whitepaper The road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Any EHR provider delivering a quality point-of-care marketing solution should be able to answer these seven questions. Sponsored by: Veradigm |
| |
|
